Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > Federal Register Notices > Quotas - 1998 > Proposed Revised Aggregate Production Quotas for 1998

Quotas - 1998

[Federal Register Volume 63, Number 137 (Friday, July 17, 1998)]
[Notices]
[Pages 38671-38674]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 98-19084]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA#167R]

Controlled Substances: Proposed Revised Aggregate Production Quotas for 1998

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed revised 1998 aggregate production quotas.


SUMMARY: This notice proposes revised 1998 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).

DATES: Comments or objections should be received on or before August 17, 1998.

ADDRESSES: Send comments or objections to the Acting Deputy Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn.: DEA Federal Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307- 7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

On November 21, 1997, a notice of established initial 1998 aggregate production quotas for certain controlled substances in Schedules I and II was published in the Federal Register (62 FR 62349). The notice proposing initial

[[Page 38672]]

1998 aggregate production quotas (62 FR 46373) stipulated that the Deputy Administrator of the DEA would adjust the quotas in early 1998 as provided for in Section 1303 of Title 21 of the Code of Federal Regulations.

The proposed revised 1998 aggregate production quotas represent those quantities of controlled substances that may be produced in the United States in 1998 to provide adequate supplies of each substance for: the estimated medical, scientific, research, and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

The proposed revisions are based on a review of 1997 year-end inventories, 1997 disposition data submitted by quota applicants, estimates of the medical needs of the United States, and other information available to the DEA.

Therefore, under the authority vested in the Attorney General by Section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, the Acting Deputy Administrator hereby proposes the following revised 1998 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base:

Basic class Previously established
initial
1998 quotas
Proposed revised
1998
quotas
SCHEDULE I
2, 5-Dimethoxyamphetamine 15,000,100 20,000,100
2, 5-Dimethoxy-4-ethylamphetamine (DOET) 2 2
3-Methylfentanyl 14 14
3-Methylthiofentanyl 2 2
3,4-Methylenedioxyamphetamine (MDA) 25 25
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 30 30
3,4-Methylenedioxymethamphetamine (MDMA) 20 20
3,4,5-Trimethoxyamphetamine 2 2
4-Bromo-2,5-Dimethoxyamphetamine (DOB) 2 2
4-Bromo-2,5-Dimethoxyphenethylamine (2-CB) 2 2
4-Methoxyamphetamine 100,100 100,100
4-Methylaminorex 2 2
4-Methyl-2,5-Dimethoxyamphetamine (DOM) 2 2
5-Methoxy-3,4-Methylenedioxyamphetamine 2 2
Acetyl-alpha-methylfentanyl 2 2
Acetylmethadol 7 7
Allylprodine 2 2
Alpha-acetylmethadol 7 7
Alpha-ethyltryptamine 2 2
Alphameprodine 2 2
Alpha-methadol 2 2
Alpha-methylfentanyl 2 2
Alphaprodine 2 2
Alpha-methylthiofentanyl 2 2
Aminorex 7 7
Beta-acetylmethadol 2 2
Beta-hydroxyfentanyl 2 2
Beta-hydroxy-3-methylfentanyl 2 2
Beta-methadol 2 2
Betaprodine 2 2
Bufotenine 2 2
Cathinone 9 9
Codeine-N-oxide 2 2
Diethyltryptamine 2 2
Difenoxin 16,000 16,000
Dihydromorphine 7 7
Dimethyltryptamine 2 2
Ethylamine Analog of PCP 5 5
Heroin 2 2
Hydroxypethidine 2 2
Lysergic acid diethylamide (LSD) 57 57
Mescaline 7 7
Methaqualone 17 17
Methcathione 11 11
Morphine-N-oxide 2 2
N-Ethylamphetamine 7 7
N-Hydroxy-3,4-Methylenedioxyamphetamine 4 4
N,N-Dimethylamphetamine 7 7
Noracymethadol 2 2
Norlevorphanol 2 2
Normethadone 7 7
Normorphine 7 7
Para-fluorofentanyl 2 2
Pholcodine 2 2
Psilocin 2 2
Psilocybin 2 2
Tetrahydrocannabinols 26,000 31,000
Thiofentanyl 2 2
Trimeperidine 2 2
SCHEDULE II
1-Phenylcyclohexylamine 15 15
1-Piperidinocyclohexanecarbonitrile (PCC) 12 12
Alfentanil 8,100 8,100
Amobarbital 12 12
Amphetamine 4,037,000 4,178,000
Cocaine 550,100 550,100
Codeine (for sale) 62,020,000 62,020,000
Codeine (for conversion) 18,460,000 23,906,000
Desoxyephedrine 1,151,000 grams of levodesoxyephedrine for use in a non-controlled, non-prescription product and 32,000 grams for methamphetamine 1,332,000 1,183,000
Dextropropoxyphene 109,500,000 109,500,000
Dihydrocodeine 189,000 46,000
Diphenoxylate 1,600,000 1,600,000
Ecgonine 651,000 651,000
Ethylmorphine 12 12
Fentanyl 202,000 202,000
Glutethimide 2 2
Hydrocodone (for sale) 13,908,000 16,314,000
Hydrocodone (for conversion) 3,000,000 3,000,000
Hydromorphone 766,000 766,000
Isomethadone 12 12
Levo-alpha-acetylmethadol (LAAM) 356,000 356,000
Levomethorphan 2 2
Levorphanol 15,000 15,000
Meperidine 9,311,000 9,745,000
Methadone (for sale) 3,790,000 5,413,000
Methadone (for conversion) 1,169,000 585,000
Methadone Intermediate 6,777,000 7,488,000
Methamphetamine (for conversion)  723,000  723,000
Methylphenidate 14,442,000 14,442,000
Morphine (for sale) 11,535,000 12,034,000
Morphine (for conversion) 75,918,000 75,918,000
Nabilone 2 2
Noroxymorphone (for sale) 25,000 25,000
Noroxymorphone (for conversion) 2,117,000 2,177,000
Opium 615,000 615,000
Oxycodone (for sale) 9,032,000 9,451,000
Oxymorphone 120,000 126,000
Pentobarbital 16,562,000 16,562,000
Phencyclidine 60 60
Phenmetrazine 2 2
Phenylacetone 10 10
Secobarbital 301,000 397,000
Sufentanil 700 1,800
Thebaine 9,580,000 13,230,000

The Acting Deputy Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances including Secs. 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations remain at zero.

All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.

In the event that comments or objections to this proposal raise one or more issues which the Acting Deputy Administrator finds warrant a hearing, the Acting Deputy Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Acting Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. The establishment of aggregate production quotas for Schedule I and II controlled substances is mandated by law and by international treaty obligations. Aggregate production quotas apply to

[[Page 38674]]

approximately 200 DEA registered bulk and dosage from manufacturers of Schedules I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Acting Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Donnie R. Marshall,
Acting Deputy Administrator.

[FR Doc. 98-19084 Filed 7-16-98; 8:45 am]

BILLING CODE 4410-09-M

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility